Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 2 hours ago
Curium strikes up to $8B deal for radiopharma rival Lantheus
about 2 hours ago
Months after reports first linked Curium to a potential Lantheus takeover, the...
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
about 6 hours ago
BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey...
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
about 8 hours ago
Not content with navigating Rezdiffra’s trajectory to blockbuster territory, Madrigal Pharmaceuticals has...
After 6-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
about 8 hours ago
One of the most closely watched vacancies in biopharma has now been...
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
about 12 hours ago
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline...
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
3 days ago
A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary...
Chutes & Ladders—Legend CEO departs without successor in place
3 days ago
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without...
From Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotech
3 days ago
Whether it's looming tariff threats or the rise of China, you need...
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
3 days ago
Apnimed has raised $192 million for its upsized IPO, with the proceeds...
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
4 days ago
Following a pair of FDA rejections for its melanoma drug, Replimune’s fortunes...
BMS CEO Boerner doesn’t ‘feel any compulsion to make deals’ despite lack of M&A this year
4 days ago
BMS may have been absent from the dealmaking spree of some of...
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
4 days ago
Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and...